6 rezultatima
The invention relates to the use of polyunsaturated fatty acids for the primary prevention of major cardiovascular events.
In particular, the invention concerns the use of polyunsaturated fatty acids of the .omega.-3 series such as eicosapentaenoic acid (EPA, C.sub.20:5 .omega.-3) docosahexaenoic
The invention relates to the use of polyunsaturated fatty acids for the primary prevention of major cardiovascular events.
In particular, the invention concerns the use of polyunsaturated fatty acids of the .omega.-3 series such as eicosapentaenoic acid (EPA, C.sub.20:5 .omega.-3), docosahexaenoic
The invention relates to the use of polyunsaturated fatty acids for the primary prevention of major cardiovascular events.
In particular, the invention concerns the use of polyunsaturated fatty acids of the .omega.-3 series such as eicosapentaenoic acid (EPA, C.sub.20:5 .omega.-3), docosahexaenoic
RELATED APPLICATION
This application claims priority to U.S. Provisional Application No. 61/669,763, filed Jul. 10, 2012, the contents of which are incorporated herein by reference in its entirety.
BACKGROUND OF THE INVENTION
Diabetes mellitus has become pandemic and according to a forecast by the
BACKGROUND OF THE INVENTION
Diabetes mellitus has become pandemic and according to a forecast by the World Health Organization, there will be a sharp increase in the number of diabetic patients by the year 2030. This is an ominous forecast, because managing the long-term complications of diabetes,
BACKGROUND OF THE INVENTION
Diabetes mellitus has become pandemic and according to a forecast by the World Health Organization, there will be a sharp increase in the number of diabetic patients by the year 2030. This is an ominous forecast, because managing the long-term complications of diabetes,